News

Bonumose Announces Key Advisory and Leadership Appointments

Bonumose, Inc. – an enzyme technology company with solutions for sugar reduction and other globally critical industries – is pleased to announce the following appointments.

  • Dr. Andrew Fordyce has accepted a key advisory role with Bonumose. Dr. Fordyce most recently was Executive Vice President and Food & Beverage Divisional Head for Novozymes, a global leader in biological solutions. His experience includes executive management in both functional and business unit organizational structures and he has had a multifaceted career that has covered biotech innovation and business strategy, marketing and business portfolio management, and process engineering and application research. Over Dr. Fordyce’s 27-year career at Novozymes he served multiple management roles including 7 years on the Novozymes’ Executive Leadership Team. Dr. Fordyce is advising Bonumose on multiple aspects of the enzyme value chain, as well as general R&D and business matters.
  • Dr. Katie Whalen. Bonumose has appointed Dr. Whalen, Director of Innovation Delivery, to the additional role of Chief of Staff. Dr. Whalen has a PhD in Biochemistry and prior to Bonumose spent 5 years at Kalsec. In her expanded role, Dr. Whalen is Bonumose’s lead on identifying and filling gaps for organizational capacity development, and also is responsible for ensuring Bonumose maintains a positive culture while scaling its production, global sales, and new product development.
  • Robert Coward. Mr. Coward recently joined Bonumose as Vice President for Finance & Accounting. Mr. Coward was with Xerox (NASDAQ: XRX), an S&P 400 company, for 28 years. Throughout his career Mr. Coward has held increasingly senior leadership roles in finance as well as operations.
  • Ross Bartels. Mr. Bartels, a recent graduate of the University of Virginia School of Law, joined Bonumose as its first in-house legal counsel. Mr. Bartels areas of focus for Bonumose include intellectual property protection, regulatory and administrative law, and general legal matters. Bonumose has over 50 granted patents globally and many more patent applications pending, and also is engaging with food ingredient regulatory bodies globally.

Bonumose is based in Albemarle County, Virginia, and was selected as a Technology Pioneer by the World Economic Forum.

Recent News

04/23/2024

AMPEL BioSolutions Selected as Member of Prestigious Federal Health Innovation ARPA-H Network

AMPEL BioSolutions has been selected as a member – or “spoke” – of the Customer Experience Hub of ARPANET-H, a prestigious nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).  This national effort is designed to accelerate commercialization of health breakthroughs for populations that urgently need them. The Customer Experience Hub in Dallas joins Boston

04/19/2024

ivWatch prevents IV leakage events at Frimley Health

Frimley Health NHS Foundation Trust has found that 100% of IV leakage incidents were prevented by a proprietary patient monitoring system from ivWatch, which could potentially save patients the pain or discomfort of adverse IV events. The initial two-week phase of the study, which was published in the British Journal of Nursing, found that continuous

04/17/2024

U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure

Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to develop the latest generation pralidoxime chloride auto-injector as a countermeasure against organophosphate or nerve agent poisoning.